New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 1, 2014
09:09 EDTEGRXEagle Pharmaceuticals' licensor granted U.S. patent for dantrolene
Eagle Pharmaceuticals announced that the United States Patent and Trademark Office has granted Patent No. 8,685,460 for the treatment of heat stroke with Eagle’s dantrolene sodium for injectable suspension. This patent issued expires in 2023. Eagle’s dantrolene formulation for the treatment of Exertional Heat Stroke was granted Orphan Drug designation by the Food and Drug Administration on September 25, 2012. Eagle is currently developing dantrolene in this new EHS indication. The company filed an NDA in January 2014 for Ryanodex in the treatment of Malignant Hyperthermia which was granted a priority review and has a PDUFA date of July 22, 2014. Ryanodex for the treatment of MH has also received Orphan Drug designation.
News For EGRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 20, 2015
06:55 EDTEGRXEagle Pharmaceuticals submits NDA for ready-to-use bivalirudin to FDA
Subscribe for More Information
May 19, 2015
08:35 EDTEGRXEagle Pharmaceuticals issued patent for bendamustine rapid infusion product
Subscribe for More Information
May 12, 2015
06:52 EDTEGRXEagle Pharmaceuticals reports Q1 EPS $1.31, consensus $1.47
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use